Tafluprost is a synthetic prostaglandin F2α analog categorized as a prostaglandin receptor agonist, primarily used in the treatment of primary open-angle glaucoma to reduce intraocular pressure. As a prodrug… Read more

![Chemical structure of (3aR,4R,5R,6aS)-2-Oxo-4-((Z)-3-oxo-4-phenoxybut-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2964393-53-9-3aR4R5R6aS-2-Oxo-4-Z-3-oxo-4-phenoxybut-1-en-1-ylhexahydro-2H-cyclopentabfuran-5-yl-benzoate.png&w=3840&q=75)
![Chemical structure of (3aR,4R,5R,6aS)-5-Hydroxy-4-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F41639-74-1-3aR4R5R6aS-5-Hydroxy-4-SE-3-hydroxy-5-phenylpent-1-en-1-ylhexahydro-2H-cyclopentabfuran-2-one.png&w=3840&q=75)









































Tafluprost is a synthetic prostaglandin F2α analog categorized as a prostaglandin receptor agonist, primarily used in the treatment of primary open-angle glaucoma to reduce intraocular pressure. As a prodrug that converts to its active acid form in vivo, the precise identification and quantification of related substances are critical during production. This category offers essential reference standards, including impurities, metabolites, and stable isotope labelled compounds, to support rigorous analytical testing. These materials are vital for pharmaceutical laboratories conducting impurity profiling and method validation, ensuring compliance with strict quality control standards throughout the development and manufacture of the active pharmaceutical ingredient.